AGE-RELATED MACULAR DEGENERATION (ARMD)
Clinical trials for AGE-RELATED MACULAR DEGENERATION (ARMD) explained in plain language.
Never miss a new study
Get alerted when new AGE-RELATED MACULAR DEGENERATION (ARMD) trials appear
Sign up with your email to follow new studies for AGE-RELATED MACULAR DEGENERATION (ARMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a daily shot save your sight? new trial targets dry AMD
Disease control OngoingThis phase 3 trial tests a daily injection of elamipretide in 313 adults aged 55+ with dry age-related macular degeneration (AMD). The goal is to see if the drug can slow the loss of light-sensing cells in the eye compared to a placebo. Participants receive either the drug or a p…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: PHASE3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated May 17, 2026 09:19 UTC
-
Can your dinner plate protect your eyesight? new study investigates
Knowledge-focused OngoingThis study looks at how genetics, Mediterranean diet, lifestyle habits, and chronic medication together influence the risk of developing age-related macular degeneration (AMD). Researchers will examine 1800 adults from the Lousã region, collecting medical history, eye exams, and …
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: NA • Sponsor: Association for Innovation and Biomedical Research on Light and Image • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC